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     Absorbance difference titrations were used to determine enzyme 
affinity for substrate and effector molecules. NMR paramagnetic 
relaxation experiments acquired data for distance measurements, 
which were then entered into the molecular docking software 
HADDOCK to model the structure of the ligand-protein complex.  
Figure 4   Stacked plot of NMR relaxation spectra for free 4-CPI. Tau interval 
increases from bottom to top, where the lowest spectrum shows τ = 0.1 s and 
the top shows τ = 12 s. Relaxation experiments used the sequence 180º-τ-
90º-detect, with 20 seconds relaxation delay and τ values of 12, 10, 6, 3, 2, 1, 
0.75, 0.5, 0.3, 0.2, and 0.1 seconds. These experiments took 16 scans at 28.5º C 
unless otherwise indicated.  
 
 
Ligand-protein complexes were modeled using distance measurements 
and the molecular docking program HADDOCK, producing images such 
as that shown in Figure 5. Preliminary trials have successfully generated 
ligand-protein models, showing that our protocols work and docking is 
possible. 
     Cytochromes P450 are a family of enzymes that metabolize most 
chemicals that enter the body, including drugs and environmental 
toxins.[1] These enzymes tend to be extremely unspecific and 
flexible, meaning they can often bind to various types of molecules 
and even multiple substrates at a time.[2] Interestingly, it is possible 
for the binding of one molecule in the active site to influence the 
binding and subsequent catalysis of a second molecule – a 
phenomenon known as cooperativity. This is responsible for drug-
drug interactions, where the effects of one drug (the substrate) are 
altered by another drug (an effector), often leading to harmful 
outcomes like toxicity.[3] 
     The process of cooperativity is poorly understood. Studies using 
the bacterial model enzyme eryF suggest that there are two distinct 
binding sites inside a larger binding pocket, and that while a 
substrate may bind to only one of these sites, effector molecules can 
bind to either.[4,5] The present experiment had three primary goals: 
(1) to reproduce literature data for the affinity of 4-CPI and 9-AP for 
P450 eryF, (2) to test how effectors (such as 9-AP) influence 
substrate binding, and (3) to ultimately develop a more precise 
model of the eryF active site.  
NMR-PRE Experiments 
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Figure 1   Absorbance difference spectra. EryF (3 
uM) was titrated separately with 4-CPI (from 0 to 
750 uM) and 9-AP (from 0 to 20 uM) [A, B], then 
presaturated with 9-AP, baselined, and titrated with 
4-CPI as done previously [C through F].   
• Literature ligand binding affinities were reproduced, with KD of 4-CPI = 26.8 uM and S50 of 9-AP = 5.8 uM.  
• Pre-saturating eryF with low concentrations of 9-AP, so that only the first site is occupied, does not affect 4-CPI binding 
affinity. Therefore, the first equivalent of 9-AP must bind somewhere other than near the heme. However, filling the 
second 9-AP binding site induces the same absorbance change as does 4-CPI binding, showing that the second equivalent of 
9-AP must bind in the same location and coordinate to the heme iron.   
• The 4-CPI protons relax differently depending on whether the ligand is enzyme-bound or free in solution, and this change 
in T1 is proportional to the fraction of ligand bound.  
• This and temperature data (not shown) show that the change in relaxation is due to the influence of the heme, making 
distance measurements possible. 
• Reducing the protein (Fe3+  Fe2+) eliminates the paramagnetic influence on T1 values and allows calculation of ligand-
iron distances.  
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Figure 5   The crystal structure of CYP2B4 in complex with 4-CPI with  Fe-C distances 
shown.[6] NMR T1 results were converted to distances using a simplified form of the 
Solomon-Bloembergen equation[7]: 
(α = fraction of ligand bound out of the total ligand concentration, r = distance from proton 
to iron, τc =              seconds , and S = spin state of the iron, which in this case is ½)   
10103 
     The T1 values of 4-CPI bound to reduced eryF did not match those obtained of free ligand, contrary to our expectation. 
Future experiments will seek to improve reproducibility of the T1 data, especially in reduced samples, by adopting one or 
more of the following changes: 
• Use a different reducing agent 
• Flushing samples with CO 
• Use a different ligand that would convert the iron to a high-spin complex (S = 5/2), which would increase the 
paramagnetic effect and possibly make T1 changes easier to detect 
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• Adding ligand causes absorbance 
to decrease at 417 nm and to 
increase at 437 nm in a manner 
proportional to the concentration of 
enzyme-ligand complex.  
• Figure 1A and B show absorbance 
difference (A437 - A417) as a function 
of ligand concentration. Titration 
data were consistent with reported 
affinity values. 
• With 9-AP-bound eryF used as a 
baseline, small concentrations of 9-
AP do not change the apparent 
affinity of 4-CPI (Figure 1D, E).  
• In contrast, a saturating amount 
of 9-AP (that fills both binding sites) 
prevents 4-CPI from further altering 
solution absorbance (Figure 1F).  
Figure 2   Example of proton relaxation curve. Data points (triangles and 
diamonds) show peak intensity after a given tau interval and are fit to a 
exponential model (curve) using the equation: 
  
where Imax describes the horizontal asymptote, τ is the relaxation delay, and 
T1 is a fitting parameter unique to the proton.  
Figure 3    T1 relaxation time as a function of enzyme concentration. As the 
concentration of enzyme increases, the T1 value decreases, representing the 
larger fraction of 4-CPI being affected by the paramagnetic iron in the eryF 
active site.  
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• The rate at which a nucleus relaxes depends on its environment, where closer proximity to a 
paramagnetic center speeds relaxation. With a paramagnetic iron in the eryF active site, protons on 
bound 4-CPI re-equilibrate with the surrounding magnetic field more quickly than do the protons 
on free ligand.  
• Because relaxation rates represent an average of all protons in solution, increasing the fraction of 
ligand bound decreases T1 values, as shown in Figure 3. This may also be explained by the equation 
shown by Figure 5, where adding enzyme increases alpha.  
• T1 values of the protons on free 4-CPI were all between 2 and 2.5 seconds, except for that of the 
peak furthest downfield, which relaxed more slowly and gave a T1 near 4.3 seconds.  
C 
F 
D 
E 
0 uM 9-AP 3 uM 9-AP 
6 uM 9-AP 100 uM 9-AP 
KD = 26 uM S50 = 5.8 uM, n = 1.2 
Literature 9-AP KD values
[3] (5 uM and 11 uM) suggest that 0, 3, 6, and 100 uM 9-AP should fill, respectively, none, only 
the first, only the first, and both effector binding sites (eryF is bound to none, one, one, and two 9-AP molecules).  
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